



## SWHP Pharmacy and Therapeutics Committee Updates

October 2018

The SWHP P&T Committee conducted a meeting on **10/23/2018** and made the following changes to the Group Choice, Group Value, and ACA Compliant formularies

### 2019 FORMULARY CHANGES

| Therapeutic Class                | Medication  | Formulary Changes        |                          | SWHP Formulary Alternatives | Effective Date |
|----------------------------------|---|--------------------------|--------------------------|-----------------------------|----------------|
|                                  |   | Group Choice             | Group Value              |                             |                |
| Nonsteroidal anti-inflammatory   | <b>Diclofenac 3% gel</b>  | Tier 3                   | Tier 3                   |                             | 1/1/2019       |
| Antidiabetic agents              | <b>Byetta<br/>Bydureon<br/>Bydureon BCise<br/>Victoza<br/>Trulicity<br/>Ozempic</b> | Tier 2                   | Tier 2                   |                             | 1/1/2019       |
| Dermatological agents            | <b>Elidel</b>   | Tier 2<br>ST added       | Tier 2<br>ST added       |                             | 1/1/2019       |
| Anti-inflammatory Topical agents | <b>Eucrisa</b>  | Tier 2<br>ST added       | Tier 2<br>ST added       |                             | 1/1/2019       |
| Topical immunosuppressive agents | <b>tacrolimus ointment</b>  | Tier 1                   | Tier 1                   |                             | 1/1/2019       |
| Immunological agents             | <b>Dupixent</b>   | SP2<br>PA criteria added | SP2<br>PA criteria added |                             | 1/1/2019       |

### 2018 FORMULARY CHANGES

| Therapeutic Class              | Medication                            | Formulary Changes                                |             |                | SWHP Formulary Alternatives | Effective Date |
|--------------------------------|---------------------------------------|--|-------------|----------------|-----------------------------|----------------|
|                                |                                       | Group Choice                                     | Group Value | ACA Compliant* |                             |                |
| Antimigraine agents            | <b>Aimovig<br/>Ajovy<br/>Emgality</b> | PA criteria added                                |             |                |                             | 10/23/2018     |
| Endocrine and metabolic agents | <b>Orilissa</b>                       | PA criteria added                                |             |                |                             | 10/23/2018     |
| Antivirals                     | <b>Synagis</b>                        | Revision of PA criteria for 2018-2019 RSV season |             |                |                             | 10/1/2018      |

#### Key

PA= Prior Authorization QL= Quantity Limit AL= Age Limit ST= Step Therapy NF=Non-formulary  
 Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brands and generics SP=Specialty  
 Group value: SP1= specialty preferred generic; SP2= specialty preferred brand; SP3= specialty non-preferred brand  
 ACA Compliant: Tier 4=specialty

\*Changes apply to all formularies if not specified.

**SWHP YEAR-TO-DATE FORMULARY GENERIC RELEASES (generic drug is available at copay listed once drug is available on the market)**

| Therapeutic Class                  | Generic Name                                  | For Brand Name          | Formulary Status        |             |               | Available Date |
|------------------------------------|---|-------------------------|-------------------------|-------------|---------------|----------------|
|                                    |   |                         | Group Choice            | Group Value | ACA Compliant |                |
| Hormone Replacement agents         | testosterone                                  | Androgel 1.62%          | Tier 3                  |             |               | October 2018   |
| Cardiovascular (PDE-5) agents      | tadalafil 2.5mg & 5mg                         | Cialis (2.5 mg and 5mg) | Tier 3                  |             |               | October 2018   |
| Central Nervous System agents      | clobazam                                      | Onfi                    | Tier 3                  | Tier 3      | Tier 4        | October 2018   |
| Anthelmintics                      | albendazole                                   | Albenza                 | Tier 1                  |             |               | October 2018   |
| Agents to treat multiple sclerosis | Dalfampridine                                 | Ampyra                  | SP                      | SP1         | Tier 4        | September 2018 |
| Antifungal agents                  | Itraconazole oral solution                    | Sporanox oral solution  | Tier 1                  | Tier 1      | NF            | September 2018 |
| Topical immune modulator           | imiquimod                                     | Zyclara                 | Tier 3                  |             |               | August 2018    |
| Antineoplastics                    | temsirolimus                                  | Torisel                 | SP                      | NF          | NF            | August 2018    |
| Topical antiparasitics             | crotamiton                                    | Eurax                   | Tier 1                  | Tier 1      | Tier 3        | August 2018    |
| Intraocular pressure reducer       | dorzolamide/ timolol/PF                       | Cosopt PF               | Tier 3                  |             |               | August 2018    |
| GI anti-inflammatory agent         | mesalamine enema                              | Rowasa SFRowasa         | Tier 1                  |             |               | August 2018    |
| Hormones                           | hydroxyprogesterone caproate                  | Makena (vial)           | SP                      | NF          | Tier 4        | July 2018      |
| Antispasmodics & anticholinergics  | Belladonna alkaloids/ phenobarbital           | Donnatal                | Tier 1                  | Tier 1      | NF            | July 2018      |
| Antineoplastics                    | bendamustine                                  | Bendeka                 | SP                      | NF          | Tier 4        | July 2018      |
| Cholesterol reducers               | colesevelam powder pack                       | Welchol                 | Tier 3                  |             |               | May 2018       |
| Vitamin K preparations             | phytonadione (Vitamin K1)                     | Mephyton                | Tier 1                  |             |               | May 2018       |
| Antiparasitics                     | praziquantel                                  | Biltricide              | Tier 3                  |             |               | April 2018     |
| Antivirals                         | ritonavir                                     | Norvir                  | Tier 1                  | SP1         | Tier 1        | March 2018     |
| Anticonvulsants                    | tiagabine                                     | Gabitril                | Tier 1                  |             |               | March 2018     |
| Oral contraceptives                | drospirenone/ ethinyl estradiol/ levomefolate | Safyral                 | Available for \$0 copay |             |               | March 2018     |

**Key**

PA= Prior Authorization QL= Quantity Limit AL= Age Limit ST= Step Therapy NF=Non-formulary  
Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brands and generics SP=Specialty  
Group value: SP1= specialty preferred generic; SP2= specialty preferred brand; SP3= specialty non-preferred brand  
ACA Compliant: Tier 4=specialty

\*Changes apply to all formularies if not specified.

|                        |                               |                  |                         |        |        |               |
|------------------------|-------------------------------|------------------|-------------------------|--------|--------|---------------|
| Proton pump inhibitors | lansoprazole ODT              | Prevacid ODT     | Tier 1                  | Tier 3 | Tier 1 | March 2018    |
| Treatment for ADHD     | methylphenidate LA 10mg cap   | Ritalin LA 10mg  | Tier 1                  |        |        | March 2018    |
| Alzheimer's therapy    | memantine ER                  | Namenda XR       | Tier 1                  |        |        | February 2018 |
| Oral contraceptives    | Tri-Vylibra                   | Ortho Tri-Cyclen | Available for \$0 copay |        |        | February 2018 |
|                        | Vylibra                       | Ortho Cyclen     | Available for \$0 copay |        |        | February 2018 |
| Acne agents            | isotretinoin capsule          | Absorica         | Tier 1                  |        |        | February 2018 |
| Antidotes              | trientine                     | Syprine          | NF                      | SP1    | NF     | February 2018 |
| Estrogens              | estradiol 0.01% vaginal cream | Estrace          | Tier 1                  |        |        | January 2018  |

### YEAR-TO-DATE FORMULARY CHANGES

| Therapeutic Class           | Medication  | Formulary Changes       |                          |               | SWHP Formulary Alternatives | Effective date |
|-----------------------------|---|-------------------------|--------------------------|---------------|-----------------------------|----------------|
|                             |   | Group Choice            | Group Value              | ACA Compliant |                             |                |
| Antineoplastics             | <b>Xatmep</b>                                     | SP                      | SP2                      | Tier 4        |                             | 10/1/2018      |
|                             |   | PA criteria added       |                          |               |                             |                |
| Antimigraine preparations   | <b>Aimovig</b>                                    | PA criteria added       |                          |               |                             | 8/28/2018      |
| Antineoplastics             | <b>Tibsovo</b>                                    | SP                      | SP2                      | Tier 4        |                             | 7/30/2018      |
| Antivirals                  | <b>Symtuza</b>                                    | SP                      | SP2                      | Tier 4        |                             | 7/23/2018      |
| Antineoplastics             | <b>Braftovi<br/>Mektovi</b>                       | SP                      | SP2                      | Tier 4        |                             | 7/2/2018       |
| Antineoplastics             | <b>Yonsa</b>                                      | SP                      | SP2                      | Tier 4        |                             | 6/4/2018       |
| Antivirals                  | <b>Symfi Lo<br/>Symfi<br/>Cimduo<br/>Biktarvy</b> | SP                      | SP2                      | Tier 4        |                             | 6/1/2018       |
| Cardiovascular agents       | <b>Entresto</b>                                   | PA criteria removed     |                          |               |                             | 6/1/2018       |
| GI drugs                    | <b>Movantik</b>                                   | Tier 3                  |                          | 6/1/2018      |                             | 6/1/2018       |
|                             | <b>Relistor SQ injection</b>                      | SP<br>PA criteria added | SP3<br>PA criteria added | Tier 3        |                             | 6/1/2018       |
|                             | <b>Relistor Oral</b>                              | NF                      | NF                       | Tier 3        |                             | 6/1/2018       |
| Antipsoriatic agents        | <b>Tremfya</b>                                    | SP                      | SP2                      | Tier 4        |                             | 6/1/2018       |
|                             |   | PA criteria added       |                          |               |                             |                |
| Various therapeutic classes | <b>hydrocodone-containing products</b>            | AL added                |                          | 6/1/2018      |                             | 6/1/2018       |
|                             | <b>Renflexis</b>                                  | SP                      | SP2                      | Tier 4        |                             | 5/1/2018       |

#### Key

PA= Prior Authorization QL= Quantity Limit AL= Age Limit ST= Step Therapy NF=Non-formulary  
Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brands and generics SP=Specialty  
Group value: SP1= specialty preferred generic; SP2= specialty preferred brand; SP3= specialty non-preferred brand  
ACA Compliant: Tier 4=specialty

\*Changes apply to all formularies if not specified.

|                                   |  |                   |     |        |                       |           |
|-----------------------------------|--|-------------------|-----|--------|-----------------------|-----------|
| Antirheumatic agents              | Inflectra                                      | NF                |     |        | Remicade<br>Renflexis | 5/1/2018  |
|                                   |  | PA criteria added |     |        |                       |           |
| GI drugs                          | Ocaliva  | PA criteria added |     |        |                       | 4/24/2018 |
| Antineoplastics                   | Erleada  | SP                | SP2 | Tier 4 |                       | 2/16/2018 |
|                                   |  | PA criteria added |     |        |                       |           |
| C1-esterase inhibitors            | Berinert<br>Haegarda                           | SP                | SP2 | Tier 4 |                       | 4/1/2018  |
|                                   |  | PA criteria added |     |        |                       |           |
|                                   | Firazyr  | SP                | SP3 | Tier 4 |                       | 4/1/2018  |
|                                   |  | PA criteria added |     |        |                       |           |
| Antivirals                        | Vemlidy  | SP                | SP2 | Tier 2 |                       | 4/1/2018  |
|                                   | Odefsey<br>Genvoya                             | SP                | SP2 | Tier 4 |                       | 4/1/2018  |
|                                   | Descovy  | Tier 2            | SP2 | Tier 3 |                       | 4/1/2018  |
| Antiretrovirals                   | Juluca   | SP                | SP2 | Tier 4 |                       | 3/1/2018  |
| Cystic Fibrosis correctors        | Symdeko  | PA Criteria added |     |        |                       | 2/27/2018 |
| Antineoplastics                   | Erleada  | SP                | SP2 | Tier 4 |                       | 2/16/2018 |
|                                   |  | PA criteria added |     |        |                       |           |
| Antitoxins and immune globulins   | Cuvitru  | PA criteria added |     |        |                       | 1/23/2018 |
| Hepatitis C antivirals            | Harvoni<br>Sovaldi                             | NF                | NF  | Tier 4 | Mavyret               | 1/1/2018  |
| Diabetic therapy                  | Jardiance<br>Synjardy<br>Invokana<br>Invokamet | Tier 2            |     |        |                       | 1/1/2018  |
| Hepatitis C antivirals            | Mavyret  | SP                | SP2 | Tier 4 |                       | 1/1/2018  |
| Bone formation stimulating agents | Tymlos<br>Forteo                               | SP                | SP2 | Tier 4 |                       | 1/1/2018  |
| Bone formation stimulating agents | raloxifene                                     | Tier 1            |     |        |                       | 1/1/2018  |
| Antifibrotic agents               | Ofev<br>Esbriet                                | PA criteria added |     |        |                       | 1/1/2018  |
| Antifungal agents                 | Cresemba                                       | PA criteria added |     |        |                       | 1/1/2018  |
| Antineoplastic agents             | Synribo  | PA criteria added |     |        |                       | 1/1/2018  |
| Interleukin antagonists           | Fasenra  | PA criteria added |     |        |                       | 1/1/2018  |
| Antidotes                         | Ferriprox                                      | PA criteria added |     |        |                       | 1/1/2018  |

**Key**

PA= Prior Authorization QL= Quantity Limit AL= Age Limit ST= Step Therapy NF=Non-formulary  
Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brands and generics SP=Specialty  
Group value: SP1= specialty preferred generic; SP2= specialty preferred brand; SP3= specialty non-preferred brand  
ACA Compliant: Tier 4=specialty

\*Changes apply to all formularies if not specified.

|                                   |  |                  |  |          |
|-----------------------------------|--|------------------|--|----------|
| Opiate agonists                   | <b>buprenorphine patch<br/>fentanyl patch<br/>hydromorphone ER<br/>methadone oral<br/>solution<br/>Methadose<br/>morphine sulfate ER<br/>oxycodone ER<br/>Nucynta ER</b> | QL added/updated |  | 1/1/2018 |
| Treatment for<br>ADHD/Narcolepsy  | <b>methylphenidate oral<br/>solution<br/>Quillivant XR<br/>Quillichew ER<br/>Daytrana</b>  | AL removed       |  | 1/1/2018 |
| Rosacea agents,<br>topical        | <b>Finacea</b>   | ST added         |  | 1/1/2018 |
| Antineoplastic<br>agents- topical | <b>diclofenac 3% gel</b>   | QL added         |  | 1/1/2018 |

**Key**

PA= Prior Authorization QL= Quantity Limit AL= Age Limit ST= Step Therapy NF=Non-formulary  
Tier 1=preferred generic; Tier 2=preferred brand; Tier 3= Non-preferred brands and generics SP=Specialty  
Group value: SP1= specialty preferred generic; SP2= specialty preferred brand; SP3= specialty non-preferred brand  
ACA Compliant: Tier 4=specialty

\*Changes apply to all formularies if not specified.